Teva Pharmaceutical Industries has petitioned the US Supreme Court to review a lower court ruling from July 2013 that had invalidated one of the company’s patents and cut more than a year off the legal protection for Copaxone.
As it stands, the Copaxone multiple-sclerosis drug will be open to generic competition in May 2014. The blockbuster treatment accounts for 50% of Teva's profits.
It is unlikely that the Supreme Court will overturn the ruling by the Federal Circuit of Appeals. In November 2013, the Supreme Court rejected Teva's motion to put the lower court ruling on hold while it prepared its petition for review.
Read the Globes press release